Broad Institute
JULY 19, 2024
A new study reveals that C1q can also enter neurons, where it influences protein production, and can accumulate within neurons over time. They also suggest that C1q influences learning, memory, and flexibility in the adult brain, potentially by interacting with specific complexes within neurons that impact protein production.
Broad Institute
JUNE 29, 2023
Now, researchers at MIT and the Broad Institute of MIT and Harvard have developed RIBOmap, a technique that lets them pinpoint and visualize the precise locations of thousands of proteins being produced within an intact tissue and even individual cells. By Sarah C.P. Williams June 29, 2023 Credit: Zeng H, Huang J, Ren J, et al.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
OCTOBER 10, 2023
The company specialises in recombinant protein production and antibody development. All of Sino Biological’s products are independently developed and produced with a stringent quality management system, and include unique bioreagents addressing areas such as cell therapy, stem cell, and infectious disease research.
The Pharma Data
OCTOBER 14, 2020
is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.
The Pharma Data
OCTOBER 18, 2021
Tofersen binds to SOD1 mRNA, allowing for its declination by RNase-H in an trouble to reduce conflation of SOD1 protein product. About Tofersen Tofersen is an antisense medicine being estimated for the implicit treatment of SOD1-ALS. Source link: [link].
Broad Institute
JANUARY 14, 2025
By Allessandra DiCorato January 14, 2025 Credit: Maria Nemchuk, Broad Communications Eric Minikel and Sonia Vallabh run a lab with a singular focus: preventing and treating prion disease within their lifetime. Its a huge privilege to have the opportunity to point these powerful new tools at our disease.
The Pharma Data
MARCH 23, 2022
Unfortunately, in a Phase 3 clinical trial, treatment with remdesivir did not make a difference in mortality for Ebola virus disease patients. Without the stop sign, viral transcription no longer follows the correct order, which has a negative impact on viral protein production,” says Fang.
Expert insights. Personalized for you.
111 
Let's personalize your content